These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 29569278)

  • 21. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
    Göhring G; Giagounidis A; Büsche G; Hofmann W; Kreipe HH; Fenaux P; Hellström-Lindberg E; Schlegelberger B
    Haematologica; 2011 Feb; 96(2):319-22. PubMed ID: 21109690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
    Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
    Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
    Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
    Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
    Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 28. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
    Jonášová A; Červinek L; Bělohlávková P; Čermák J; Beličková M; Rohoň P; Černá O; Hochová I; Šišková M; Kačmářová K; Janoušová E
    Vnitr Lek; 2015 Dec; 61(12):1028-33. PubMed ID: 26806497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
    Komrokji RS; List AF
    Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
    Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
    List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
    Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
    BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
    Mortensen TB; Frederiksen H; Marcher CW; Preiss B
    BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.